BACKGROUND: The B cell leukemia 11A (BCL11A) gene was identified as a proto-oncogene in hematopoietic cell malignancies and breast cancer. Alternative RNA splicing generates three main transcripts designated as Extra-long (XL; 5.9 kb/125 kD), Long (L; 3.8 kb/100 kD) and Short (S; 2.4 kb/35 kD). Our previous study results demonstrated that BCL11A expression levels were specifically upregulated in non-small cell lung cancer (NSCLC) tissues, especially in squamous cell carcinoma (SCC) and large cell carcinoma (LCC). METHODS: In this study, we detected the BCL11A protein isoforms with immunohistochemistry (IHC) method in NSCLC with in a cohort (n=40) of BCL11A overexpression NSCLC patients. All 40 cases were BCL11A overexpression including 27 SCCs, 8 LCCs and 5 adenocarcinomas (ACs). Relationship between BCL11A isoforms and the clinicopathological parameters were also analyzed. RESULTS: Compare to the BCL11A-L and S isoforms, the BCL11A-XL isoform was specifically expressed in SCC and LCC (P=0.006). There were 19 (19/40, 47.5%) cases positive for BCL11A-XL expression, SCC accounted for 63.2% (12/19) and LCC accounted for 36.8% (7/19). The survival analysis indicated that BCL11A-XL expression was an independent prognostic factor for disease-free survival (DFS) [hazards ratio (HR) 0.246; 95% confidence interval (CI), 0.065-0.939, P=0.040] but not for overall survival (OS) in patients with SCC and LCC. CONCLUSIONS: Our results demonstrated that the BCL11A-XL isoform might be a potential prognostic biomarker of SCC and LCC.
BACKGROUND: The B cell leukemia 11A (BCL11A) gene was identified as a proto-oncogene in hematopoietic cell malignancies and breast cancer. Alternative RNA splicing generates three main transcripts designated as Extra-long (XL; 5.9 kb/125 kD), Long (L; 3.8 kb/100 kD) and Short (S; 2.4 kb/35 kD). Our previous study results demonstrated that BCL11A expression levels were specifically upregulated in non-small cell lung cancer (NSCLC) tissues, especially in squamous cell carcinoma (SCC) and large cell carcinoma (LCC). METHODS: In this study, we detected the BCL11A protein isoforms with immunohistochemistry (IHC) method in NSCLC with in a cohort (n=40) of BCL11A overexpression NSCLCpatients. All 40 cases were BCL11A overexpression including 27 SCCs, 8 LCCs and 5 adenocarcinomas (ACs). Relationship between BCL11A isoforms and the clinicopathological parameters were also analyzed. RESULTS: Compare to the BCL11A-L and S isoforms, the BCL11A-XL isoform was specifically expressed in SCC and LCC (P=0.006). There were 19 (19/40, 47.5%) cases positive for BCL11A-XL expression, SCC accounted for 63.2% (12/19) and LCC accounted for 36.8% (7/19). The survival analysis indicated that BCL11A-XL expression was an independent prognostic factor for disease-free survival (DFS) [hazards ratio (HR) 0.246; 95% confidence interval (CI), 0.065-0.939, P=0.040] but not for overall survival (OS) in patients with SCC and LCC. CONCLUSIONS: Our results demonstrated that the BCL11A-XL isoform might be a potential prognostic biomarker of SCC and LCC.
Entities:
Keywords:
BCL11A-XL; non-small cell lung cancer (NSCLC); prognosis
Authors: Vijay G Sankaran; Tobias F Menne; Jian Xu; Thomas E Akie; Guillaume Lettre; Ben Van Handel; Hanna K A Mikkola; Joel N Hirschhorn; Alan B Cantor; Stuart H Orkin Journal: Science Date: 2008-12-04 Impact factor: 47.728
Authors: Saul Grinstein; Maria Victoria Preciado; Paolo Gattuso; Paola A Chabay; William H Warren; Elena De Matteo; Victor E Gould Journal: Cancer Res Date: 2002-09-01 Impact factor: 12.701
Authors: T Inaba; N Oku; H Gotoh; S Murakami; N Oku; K Itoh; Y Ura; S Nakanishi; C Shimazaki; M Nakagawa Journal: Leukemia Date: 1991-08 Impact factor: 11.528
Authors: M A Weniger; K Pulford; S Gesk; S Ehrlich; A H Banham; L Lyne; J I Martin-Subero; R Siebert; M J S Dyer; P Möller; T F E Barth Journal: Leukemia Date: 2006-07-27 Impact factor: 11.528
Authors: K Pulford; A H Banham; L Lyne; M Jones; G C Ippolito; H Liu; P W Tucker; G Roncador; E Lucas; S Ashe; L Stockwin; R Walewska; L Karran; R D Gascoyne; D Y Mason; M J S Dyer Journal: Leukemia Date: 2006-05-18 Impact factor: 11.528
Authors: Hui Liu; Gregory C Ippolito; Jason K Wall; Teresa Niu; Loren Probst; Baeck-Seung Lee; Karen Pulford; Alison H Banham; Luke Stockwin; Arthur L Shaffer; Louis M Staudt; Chhaya Das; Martin J S Dyer; Philip W Tucker Journal: Mol Cancer Date: 2006-05-16 Impact factor: 27.401
Authors: Andrea Angius; Giovanna Pira; Paolo Cossu-Rocca; Giovanni Sotgiu; Laura Saderi; Maria Rosaria Muroni; Patrizia Virdis; Daniela Piras; Rallo Vincenzo; Ciriaco Carru; Donatella Coradduzza; Maria Gabriela Uras; Pierina Cottu; Alessandro Fancellu; Sandra Orrù; Paolo Uva; Maria Rosaria De Miglio Journal: J Cancer Res Clin Oncol Date: 2022-08-28 Impact factor: 4.322
Authors: Kyren A Lazarus; Fazal Hadi; Elisabetta Zambon; Karsten Bach; Maria-Francesca Santolla; Julie K Watson; Lucia L Correia; Madhumita Das; Rosemary Ugur; Sara Pensa; Lukas Becker; Lia S Campos; Graham Ladds; Pentao Liu; Gerard I Evan; Frank M McCaughan; John Le Quesne; Joo-Hyeon Lee; Dinis Calado; Walid T Khaled Journal: Nat Commun Date: 2018-08-20 Impact factor: 14.919